178 related articles for article (PubMed ID: 37071495)
1. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.
Gou X; Kim BJ; Anurag M; Lei JT; Young MN; Holt MV; Fandino D; Vollert CT; Singh P; Alzubi MA; Malovannaya A; Dobrolecki LE; Lewis MT; Li S; Foulds CE; Ellis MJ
Cancer Res; 2023 Oct; 83(19):3237-3251. PubMed ID: 37071495
[TBL] [Abstract][Full Text] [Related]
2. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
Wu J; Subbiah V
Cancer Res; 2023 Oct; 83(19):3159-3161. PubMed ID: 37779428
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
4. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.
Lei JT; Shao J; Zhang J; Iglesia M; Chan DW; Cao J; Anurag M; Singh P; He X; Kosaka Y; Matsunuma R; Crowder R; Hoog J; Phommaly C; Goncalves R; Ramalho S; Peres RMR; Punturi N; Schmidt C; Bartram A; Jou E; Devarakonda V; Holloway KR; Lai WV; Hampton O; Rogers A; Tobias E; Parikh PA; Davies SR; Li S; Ma CX; Suman VJ; Hunt KK; Watson MA; Hoadley KA; Thompson EA; Chen X; Kavuri SM; Creighton CJ; Maher CA; Perou CM; Haricharan S; Ellis MJ
Cell Rep; 2018 Aug; 24(6):1434-1444.e7. PubMed ID: 30089255
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
Gou X; Anurag M; Lei JT; Kim BJ; Singh P; Seker S; Fandino D; Han A; Rehman S; Hu J; Korchina V; Doddapaneni H; Dobrolecki LE; Mitsiades N; Lewis MT; Welm AL; Li S; Lee AV; Robinson DR; Foulds CE; Ellis MJ
Cancer Res; 2021 Dec; 81(24):6259-6272. PubMed ID: 34711608
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
[TBL] [Abstract][Full Text] [Related]
7. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
8. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
9. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Dustin D; Gu G; Beyer AR; Herzog SK; Edwards DG; Lin H; Gonzalez TL; Grimm SL; Coarfa C; Chan DW; Kim BJ; De La O JP; Ellis MJ; Liu D; Li S; Welm AL; Fuqua SAW
Br J Cancer; 2021 Jan; 124(1):191-206. PubMed ID: 33257837
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.
Brett JO; Ritterhouse LL; Newman ET; Irwin KE; Dawson M; Ryan LY; Spring LM; Rivera MN; Lennerz JK; Dias-Santagata D; Ellisen LW; Bardia A; Wander SA
Oncologist; 2023 Feb; 28(2):172-179. PubMed ID: 36493359
[TBL] [Abstract][Full Text] [Related]
12. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
Vitale SR; Ruigrok-Ritstier K; Timmermans AM; Foekens R; Trapman-Jansen AMAC; Beaufort CM; Vigneri P; Sleijfer S; Martens JWM; Sieuwerts AM; Jansen MPHM
BMC Cancer; 2022 Feb; 22(1):165. PubMed ID: 35151276
[TBL] [Abstract][Full Text] [Related]
14. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
Patel JM; Jeselsohn RM
Adv Exp Med Biol; 2022; 1390():171-194. PubMed ID: 36107319
[TBL] [Abstract][Full Text] [Related]
15. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
16. ESR1 mutations in breast cancer.
Dustin D; Gu G; Fuqua SAW
Cancer; 2019 Nov; 125(21):3714-3728. PubMed ID: 31318440
[TBL] [Abstract][Full Text] [Related]
17. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
19. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
20. Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
Udden SN; Wang Q; Kumar S; Malladi VS; Wu SY; Wei S; Posner BA; Geboers S; Williams NS; Liu Y; Sharma JK; Mani RS; Malladi S; Parra K; Hofstad M; Raj GV; Larios JM; Jagsi R; Wicha MS; Park BH; Gupta GP; Chinnaiyan AM; Chiang CM; Alluri PG
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35881485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
